Financials VALBIOTIS

Equities

Market Closed - Euronext Paris Other stock markets 16:35:07 03/05/2024 BST			5-day change	1st Jan Change
4.13 ^EUR	+0.49%		+5.90%	-17.40%

04-26	Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	13.48	16.09	46.58	66.56	44.66	65.14	65.14	-
Enterprise Value (EV) ¹	6.061	8.057	39.01	52.33	31.01	62.05	47.01	30.97
P/E ratio	-	-1.9 x	-11.7 x	-7.29 x	-2.98 x	-4.42 x	-4.69 x	51.6 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	8.93 x	8.41 x	9.13 x	24.7 x	15.9 x	9.11 x	5.92 x	2.7 x
EV / Revenue	4.02 x	4.21 x	7.65 x	19.4 x	11 x	9.11 x	4.27 x	1.28 x
EV / EBITDA	-	-	-16.5 x	-6.95 x	-2.77 x	-5.03 x	-7.46 x	-34.4 x
EV / FCF	-1.15 x	-1.54 x	16.5 x	-7.01 x	-3.33 x	-4.4 x	-4.25 x	-7.29 x
FCF Yield	-86.9%	-65%	6.05%	-14.3%	-30%	-22.7%	-23.5%	-13.7%
Price to Book	-	-	6.53 x	4.66 x	3.34 x	3.3 x	3.01 x	1.38 x
Nbr of stocks (in thousands)	4,135	7,183	7,686	9,717	12,405	15,773	15,773	-
Reference price ²	3.260	2.240	6.060	6.850	3.600	4.130	4.130	4.130
Announcement Date	08/03/19	21/04/20	16/03/21	15/03/22	15/03/23	26/04/24	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	1.509	1.913	5.099	2.693	2.814	6.809	11	24.13
EBITDA ¹	-	-	-2.37	-7.534	-11.17	-9	-6.3	-0.9
EBIT ¹	-4.876	-5.157	-3.407	-8.475	-12.03	-7.18	-6.7	4.6
Operating Margin	-323.13%	-269.58%	-66.82%	-314.7%	-427.36%	-105.45%	-60.91%	19.06%
Earnings before Tax (EBT)	-	-	-3.829	-	-	-	-	-
Net income ¹	-4.967	-5.504	-3.829	-8.681	-12.31	-7.368	-6.8	3.2
Net margin	-329.16%	-287.72%	-75.09%	-322.35%	-437.53%	-108.21%	-61.82%	13.26%
EPS ²	-	-1.180	-0.5200	-0.9400	-1.210	-0.9350	-0.8800	0.0800
Free Cash Flow ¹	-5.269	-5.236	2.361	-7.462	-9.303	-10.3	-11.05	-4.25
FCF margin	-349.17%	-273.71%	46.3%	-277.09%	-330.6%	-167.03%	-100.45%	-17.61%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	08/03/19	21/04/20	16/03/21	15/03/22	15/03/23	26/04/24	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	7.42	8.03	7.57	14.2	13.7	19.8	18.1	34.2
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-5.27	-5.24	2.36	-7.46	-9.3	-10.3	-11.1	-4.25
ROE (net income / shareholders' equity)	-	-	-49.7%	-81%	-	-57.7%	-60.5%	-22.3%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	15.3%
Assets ¹	-	-	-	-	-	-	-	20.92
Book Value Per Share ²	-	-	0.9300	1.470	1.080	1.250	1.370	3.000
Cash Flow per Share ²	-	-1.050	0.3600	-0.7800	-0.9100	-0.8000	0.1000	1.300
Capex ¹	0.72	0.29	0.33	0.31	0.11	0.3	0.35	0.35
Capex / Sales	47.91%	15.16%	6.51%	11.36%	3.94%	4.86%	3.18%	1.45%
Announcement Date	08/03/19	21/04/20	16/03/21	15/03/22	15/03/23	26/04/24	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.13 EUR

Average target price

10.07 EUR

Spread / Average Target

+143.75%

	1st Jan change	Capi.
VALBIOTIS	-17.40%	70.17M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B